Basmisanil(RG1662)

  Cat. No.:  DC9935   Featured
Chemical Structure
1159600-41-5
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Basmisanil is a highly selective inverse agonist/negative allosteric modulator of α5 subunit-containing GABAA receptors which is under development by Roche for the treatment of cognitive impairment associated with Down syndrome.
Cas No.: 1159600-41-5
Chemical Name: Basmisanil
Synonyms: Basmisanil;RG1662;RO5186582;(1,1-Dioxo-4-thiomorpholinyl)[6-[[3-(4-fluorophenyl)-5-methylisoxazol-4-yl]methoxy]pyridin-3-yl]methanone;RG 1662;788PET5SUA;(1,1-Dioxidothiomorpholino)(6-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)pyridin-3-yl)methanone;Basmisanil [INN];(1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone;Basmisanil [USAN:INN];Basmisani;Basmisanil(RG1662);Basmisanil (USAN/INN);GTPL10427;VCGRFBXVSFAGGA-UHFFFAOYSA-N;BDBM133427;BCP19013
SMILES: S1(C([H])([H])C([H])([H])N(C(C2=C([H])N=C(C([H])=C2[H])OC([H])([H])C2=C(C([H])([H])[H])ON=C2C2C([H])=C([H])C(=C([H])C=2[H])F)=O)C([H])([H])C1([H])[H])(=O)=O
Formula: C21H20FN3O5S
M.Wt: 445.4640
Purity: >98%
Sotrage: 4°C for 1 year, -20°C for more than 2 years
Description: Basmisanil is a highly selective GABAAα5 negative allosteric modulator.
References: [1]. Myers JF, et al. Quantification of [11C]Ro15-4513 GABAAα5 specific binding and regional selectivity in humans. J Cereb Blood Flow Metab. 2016 Jul 27.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
2018-0101
Cat. No. Product name Field of application
DC9935 Basmisanil(RG1662) Basmisanil is a highly selective inverse agonist/negative allosteric modulator of α5 subunit-containing GABAA receptors which is under development by Roche for the treatment of cognitive impairment associated with Down syndrome.
X